Apixaban and rivaroxaban's physiologically‐based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side
Abstract When used in real‐world conditions, substantial interindividual variations in direct oral anticoagulant (DOAC) plasma concentrations are observed for a given dose, leading to a risk of over‐ or under‐exposure and clinically significant adverse events. Physiologically‐based pharmacokinetic (...
Saved in:
Main Authors: | Jean Terrier (Author), Frédéric Gaspar (Author), Pauline Gosselin (Author), Olivier Raboud (Author), Camille Lenoir (Author), Victoria Rollason (Author), Chantal Csajka (Author), Caroline Samer (Author), Pierre Fontana (Author), Youssef Daali (Author), Jean‐Luc Reny (Author), for the OptimAT study group (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study
by: Frédéric Gaspar, et al.
Published: (2023) -
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
by: Frost C, et al.
Published: (2014) -
Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect
by: Kuntheavy Ing Lorenzini, et al.
Published: (2016) -
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
by: Frost C, et al.
Published: (2018) -
In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
by: Zhi Wang, et al.
Published: (2023)